High Court Backs Challenge to HSE Over Weight-Loss Injections

The High Court has granted permission to a vulnerable teenager to bring a judicial review challenging the Health Service Executive over its refusal to reimburse the cost of life-changing weight-loss injections. Delivering judgment, Ms Justice Mary Rose Gearty determined that the state health agency’s administrative decision was amenable to judicial review and that the applicant had established an arguable case regarding the rationality of the refusal. The proceedings spotlight the growing legal and financial tensions surrounding access to modern GLP-1 receptor agonists under Irish public healthcare frameworks.

Life-Changing Treatment and Mounting Financial Strain

The applicant, a seven-foot-tall teenager living with a rare congenital syndrome, had suffered from severe, life-threatening obesity that compounded a range of complex medical difficulties. His condition had aggravated an underlying cardiovascular defect, produced severe orthopaedic complications, and fostered behavioural challenges that significantly complicated his daily care regime. In July 2025, clinicians prescribed him the weight-loss medication Wegovy, leading to a dramatic four-stone weight reduction that noticeably mitigated his aggressive outbursts and restored a degree of physical mobility and personal independence.

Despite holding a standard medical card, the minor was unable to obtain the drug through routine community drug schemes, as the State does not routinely reimburse such treatments for weight management. His mother, who acts as his full-time carer and sole provider, was forced to fund the prescription privately at an ongoing cost of approximately €150 per calendar month. Finding this ongoing financial commitment impossible to sustain, she submitted an application to the HSE seeking exceptional funding under its discretionary hardship mechanism.

The Statutory Framework and Discretionary Relief

The application for financial support was brought pursuant to Section 23 of the Health (Pricing and Supply of Medical Goods) Act 2013. Under Section 17 of the legislation, the HSE maintains a formal reimbursement list designating medicines eligible for state coverage across community drug arrangements. However, Section 23 creates a specific discretionary hardship pathway, empowering the executive to supply non-listed products where a patient demonstrates clinical necessity and where no suitable alternative medication exists on the approved list.

In May 2026, the HSE issued a formal decision rejecting the teenager’s reimbursement claim. The executive justified its refusal by identifying three secondary medical conditions, asserting that a listed alternative drug was theoretically available, and cautioning that granting approval could create a precedent affecting numerous other patients. Crucially, the decision record appeared to omit any meaningful evaluation of the teenager’s rare primary syndrome, which his treating clinicians argued made standard listed alternatives medically unsuitable.

Judicial Review and the Rationality of Administrative Discretion

Acting as his next friend, the applicant’s mother initiated judicial review proceedings before the High Court, seeking an order of certiorari to quash the decision alongside declaratory reliefs. In opposing the leave application, legal representatives for the HSE contended that decisions governing financial reimbursement are inherently matters of broad resource-allocation policy rather than quasi-judicial determinations, arguing that the courts should exercise significant restraint and refuse leave to intervene in administrative health spending.

Ms Justice Gearty rejected the proposition that the decision was insulated from legal oversight. The court affirmed that where the Oireachtas vests a statutory body with discretionary power under Section 23, the exercise of that power remains subject to fundamental administrative law principles, including rationality, reasonableness, and the requirement to consider all relevant clinical factors. The judge found that the applicant had met the requisite legal threshold demonstrating an arguable ground that the executive acted irrationally by failing to evaluate the full clinical context of his rare syndrome.

Implications for Patients Navigating State Schemes

The High Court formally granted the minor leave to apply for certiorari to quash the HSE’s refusal, while declining leave for ancillary declaratory reliefs on the basis that they were unnecessary. The substantive hearing will now examine whether the executive’s internal decision-making process adhered to fair procedures and whether blanket administrative considerations overrode individual medical necessity under the 2013 Act.

The case marks an important milestone for patients seeking specialised or non-formulary medications through discretionary channels in Ireland. As public demand for breakthrough metabolic therapies intensifies, the ruling underscores that state bodies exercising statutory discretion must rigorously weigh individual medical complexities against broad budgetary policies, ensuring that decisions impacting vulnerable patients are legally robust, fully reasoned, and clinically sound.